Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fumoleau

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Seminars in Oncology|May 2, 2003
Gemcitabine combined with docetaxel in metastatic breast cancerPierre Fumoleau
The Breast Journal|November 22, 2011
The paradox of triple negative breast cancer: novel approaches to treatmentMonica Fornier, Pierre Fumoleau
Seminars in Oncology|October 19, 2004
Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancerPierre Fumoleau, David Cameron
Bulletin Du Cancer|April 10, 2002
[Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice]Mario Campone, Pierre Fumoleau
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|September 3, 2004
The vital role of education and information in patients receiving capecitabine (Xeloda)Ian Chau, Sally Legge, Pierre Fumoleau
Bulletin Du Cancer|May 19, 2005
[Cardiac dysfunction induced by trastuzumab]Mario Campone, Emmanuelle Bourbouloux, Pierre Fumoleau
Bulletin Du Cancer|September 6, 2003
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]Mario Campone, Jean-Louis Merlin, Pierre Fumoleau
Critical Reviews in Oncology/Hematology|July 26, 2005
Taxanes in adjuvant breast cancer setting: which standard in Europe?Mario Campone, Pierre Fumoleau, Emmanuelle Bourbouloux, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2002
The effects of food on the pharmacokinetic profile of oral vinorelbineRoland Bugat, Philippe Variol, Henri Roché, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 3, 2003
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patientsEmmanuelle Comets, Kazumasa Ikeda, Paulo Hoff, et al.
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Seminars in Oncology|May 2, 2003
Gemcitabine combined with docetaxel in metastatic breast cancerPierre Fumoleau
The Breast Journal|November 22, 2011
The paradox of triple negative breast cancer: novel approaches to treatmentMonica Fornier, Pierre Fumoleau
Seminars in Oncology|October 19, 2004
Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancerPierre Fumoleau, David Cameron
Bulletin Du Cancer|April 10, 2002
[Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice]Mario Campone, Pierre Fumoleau
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|September 3, 2004
The vital role of education and information in patients receiving capecitabine (Xeloda)Ian Chau, Sally Legge, Pierre Fumoleau
Bulletin Du Cancer|May 19, 2005
[Cardiac dysfunction induced by trastuzumab]Mario Campone, Emmanuelle Bourbouloux, Pierre Fumoleau
Bulletin Du Cancer|September 6, 2003
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application]Mario Campone, Jean-Louis Merlin, Pierre Fumoleau
Critical Reviews in Oncology/Hematology|July 26, 2005
Taxanes in adjuvant breast cancer setting: which standard in Europe?Mario Campone, Pierre Fumoleau, Emmanuelle Bourbouloux, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2002
The effects of food on the pharmacokinetic profile of oral vinorelbineRoland Bugat, Philippe Variol, Henri Roché, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 3, 2003
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patientsEmmanuelle Comets, Kazumasa Ikeda, Paulo Hoff, et al.
Pageof 11